Logo image of BLI

BERKELEY LIGHTS INC (BLI) Stock Fundamental Analysis

NASDAQ:BLI - Nasdaq - US0843101017 - Common Stock - Currency: USD

1.2  -0.07 (-5.88%)

After market: 1.21 +0.01 (+0.83%)

Fundamental Rating

2

Taking everything into account, BLI scores 2 out of 10 in our fundamental rating. BLI was compared to 57 industry peers in the Life Sciences Tools & Services industry. BLI has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, BLI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BLI had negative earnings in the past year.
BLI had a negative operating cash flow in the past year.
In the past 5 years BLI always reported negative net income.
BLI had a negative operating cash flow in each of the past 5 years.
BLI Yearly Net Income VS EBIT VS OCF VS FCFBLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

BLI has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BLI Yearly ROA, ROE, ROICBLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 -20 -40 -60

1.3 Margins

BLI's Gross Margin of 68.43% is amongst the best of the industry. BLI outperforms 89.06% of its industry peers.
BLI's Gross Margin has declined in the last couple of years.
BLI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.43%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.73%
GM growth 5YN/A
BLI Yearly Profit, Operating, Gross MarginsBLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

BLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BLI has been increased compared to 1 year ago.
BLI has a worse debt/assets ratio than last year.
BLI Yearly Shares OutstandingBLI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 20M 40M 60M
BLI Yearly Total Debt VS Total AssetsBLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -2.23, we must say that BLI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -2.23, BLI is not doing good in the industry: 81.25% of the companies in the same industry are doing better.
BLI has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
BLI has a Debt to Equity ratio (0.10) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -2.23
ROIC/WACCN/A
WACC8.97%
BLI Yearly LT Debt VS Equity VS FCFBLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 100M 200M

2.3 Liquidity

BLI has a Current Ratio of 3.89. This indicates that BLI is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.89, BLI perfoms like the industry average, outperforming 51.56% of the companies in the same industry.
BLI has a Quick Ratio of 3.48. This indicates that BLI is financially healthy and has no problem in meeting its short term obligations.
BLI has a Quick ratio of 3.48. This is comparable to the rest of the industry: BLI outperforms 51.56% of its industry peers.
Industry RankSector Rank
Current Ratio 3.89
Quick Ratio 3.48
BLI Yearly Current Assets VS Current LiabilitesBLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

BLI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.64%.
Looking at the last year, BLI shows a decrease in Revenue. The Revenue has decreased by -7.96% in the last year.
BLI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.51% yearly.
EPS 1Y (TTM)-33.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.69%
Revenue 1Y (TTM)-7.96%
Revenue growth 3Y11.51%
Revenue growth 5YN/A
Sales Q2Q%-23.05%

3.2 Future

Based on estimates for the next years, BLI will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.00% on average per year.
The Revenue is expected to grow by 17.80% on average over the next years. This is quite good.
EPS Next Y24.43%
EPS Next 2Y15.53%
EPS Next 3Y19%
EPS Next 5YN/A
Revenue Next Year11.33%
Revenue Next 2Y15.66%
Revenue Next 3Y17.8%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BLI Yearly Revenue VS EstimatesBLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M
BLI Yearly EPS VS EstimatesBLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BLI Price Earnings VS Forward Price EarningsBLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BLI Per share dataBLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

BLI's earnings are expected to grow with 19.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.53%
EPS Next 3Y19%

More info and screens

0

5. Dividend

5.1 Amount

BLI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BERKELEY LIGHTS INC

NASDAQ:BLI (3/21/2023, 8:00:01 PM)

After market: 1.21 +0.01 (+0.83%)

1.2

-0.07 (-5.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-23 2023-02-23/amc
Earnings (Next)05-08 2023-05-08/amc
Inst Owners5.31%
Inst Owner Change0%
Ins Owners2.36%
Ins Owner Change0%
Market Cap47.72M
Analysts69.09
Price Target7.65 (537.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-28.89%
Min EPS beat(2)-51.47%
Max EPS beat(2)-6.32%
EPS beat(4)0
Avg EPS beat(4)-19.23%
Min EPS beat(4)-51.47%
Max EPS beat(4)-1.55%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-15.01%
Min Revenue beat(2)-28.18%
Max Revenue beat(2)-1.84%
Revenue beat(4)0
Avg Revenue beat(4)-10.57%
Min Revenue beat(4)-28.18%
Max Revenue beat(4)-1.06%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-26.83%
PT rev (3m)-26.83%
EPS NQ rev (1m)-4.32%
EPS NQ rev (3m)5.44%
EPS NY rev (1m)-15.47%
EPS NY rev (3m)-15.47%
Revenue NQ rev (1m)-2.29%
Revenue NQ rev (3m)-19.43%
Revenue NY rev (1m)-4.87%
Revenue NY rev (3m)-4.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.61
P/FCF N/A
P/OCF N/A
P/B 0.34
P/tB 0.34
EV/EBITDA N/A
EPS(TTM)-1.43
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.2
OCFYN/A
SpS1.98
BVpS3.57
TBVpS3.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.43%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.73%
GM growth 5YN/A
F-Score4
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.69%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.89
Quick Ratio 3.48
Altman-Z -2.23
F-Score4
WACC8.97%
ROIC/WACCN/A
Cap/Depr(3y)145.63%
Cap/Depr(5y)157.51%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.69%
EPS Next Y24.43%
EPS Next 2Y15.53%
EPS Next 3Y19%
EPS Next 5YN/A
Revenue 1Y (TTM)-7.96%
Revenue growth 3Y11.51%
Revenue growth 5YN/A
Sales Q2Q%-23.05%
Revenue Next Year11.33%
Revenue Next 2Y15.66%
Revenue Next 3Y17.8%
Revenue Next 5YN/A
EBIT growth 1Y-33.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.77%
EBIT Next 3Y22.9%
EBIT Next 5YN/A
FCF growth 1Y19.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.52%
OCF growth 3YN/A
OCF growth 5YN/A